Physician profile
Michael Armand Ament
NPI 1437111010
$457,388.85
in general payments reported to CMS, 2019-2025
22 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110K · 2020: $146K · 2021: $147K · 2022: $50K · 2023: $3,340 · 2024: $908 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,925 · Food and Beverage: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,925.00 |
| Food and Beverage | $2,145.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $190,784.74 | 2019-2022 | |
| Allergan, INC. | $62,843.70 | 2019-2022 | |
| Abbvie INC. | $62,715.82 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Biohaven Pharmaceutical Holding Company LTD. | $42,367.73 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $37,514.36 | 2019-2025 | Ajovy |
| Biohaven Pharmaceuticals, INC. | $27,377.71 | 2020-2021 | |
| Amgen INC. | $16,366.17 | 2019-2024 | Uplizna |
| Biodelivery Sciences International, INC. | $8,618.66 | 2021 | |
| Lundbeck LLC | $5,785.21 | 2020-2025 | Vyepti |
| Eli Lilly and Company | $2,206.34 | 2019-2021 | |
| Axsome Therapeutics, INC. | $290.17 | 2025 | Symbravo |
| Pfizer INC. | $165.65 | 2021-2025 | |
| Impel Pharmaceuticals INC. | $81.08 | 2023 | Trudhesa |
| Celgene Corporation | $81.02 | 2022-2024 | Reblozyl |
| Upsher-Smith Laboratories LLC | $54.40 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $44.22 | 2020 | |
| Promius Pharma LLC | $22.60 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.88 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.27 | 2023 | Nuedexta |
| Amneal Pharmaceuticals LLC | $14.30 | 2019 | |
| Zyla Life Sciences, INC. | $12.13 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ament listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.